You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Exhaled breath drug detection using differential mobility spectrometry

    SBC: VOX BIOMEDICAL LLC            Topic: NIDA

    Project Summary This proposal seeks to expand upon breath analysis technology that is being actively studied as the focus of NIH grant #6R42DA049655-02 and leverage this technology for rapid COVID-19 diagnostics. There is a dire need for sensitive and specific diagnostic tests for COVID-19 that can be performed quickly. The differential mobility spectrometry (DMS) breath analysis technology curren ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Peptidomic Rapid Point-of-Care TB Diagnostic

    SBC: NEW YORK UNIVERSITY            Topic: NIAID

    DESCRIPTION (provided by applicant): The goals of this proposal are to devise rapid serological tests that can replace the sputum smear test for the diagnosis of active TB and meets the WHO specifications to replace microscopy in resource-limited countries based on immunodominant peptides from three M. tb cell-wall proteins. Although direct smear microscopy is highly specific, the test is tedious, ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis

    SBC: RIPARIAN PHARMACEUTICALS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis Cardiovascular disease is the leading cause of morbidity and mortality in the United States and is an emerging epidemic world-wide. In particular, atherosclerosis is a life-threatening disease strongly associated with risk factors such as elevated cholesterol levels, high blood pressure and d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A software tool for objective identification of concussion-related vision disorders using a novel eye-tracking device

    SBC: Oculogica Inc.            Topic: 102

    ABSTRACT This project will create the first objective measurement toolthe VisBoxfor the vision subtype of concussionVSCThis will enable physicians to identify VSC without an eye care professionalfor referral to a vision specialist for personalized vision therapy recommendationsThe persistence of concussion symptoms beyond several weeks is often a life altering situation for affected individualsand ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Dynasore Analogues for Ocular Surface Protection

    SBC: MEDCHEM PARTNERS LLC            Topic: NEI

    7. PROJECT SUMMARY Diseases of the ocular surface are among the top reasons for visits to eye care practitioners. These conditions can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain, redness and itching, and in severe cases, blindness due to corneal scarring. Many ocular surface diseases are initiated by loss of tear film homeostasis and can be ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and exis ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Discovery of Zika virus therapeutics using a replicon assay

    SBC: MICROBIOTIX, INC.            Topic: R

    ABSTRACT The Zika virusZIKVis the cause of an explosive pandemic of infections across South and Central Americathe Caribbeanand the southeastern region of the United StatesZIKV is a flavivirusa family of small positive strand RNA viruses that includes Dengue virusDENVWest Nile virusWNVYellow fever virusYFVand hepatitis C virusHCVZIKV is transmitted to humans by mosquitoes of the Aedes genusFor the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government